refractory hairy cell leukemia (Cancer)
Information
- Disease name
- refractory hairy cell leukemia
- Disease ID
- DOID:711
- Description
- "A refractory hematologic cancer that is a mature B cell cancer that does not yield readily to treatment." [url:http\://en.wikipedia.org/wiki/Hairy_cell_leukemia, url:http\://www.medterms.com/script/main/art.asp?articlekey=5274]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01815749 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | October 8, 2013 | September 27, 2024 |
| NCT04578600 | Active, not recruiting | Phase 1 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | October 23, 2020 | December 2024 |
| NCT04681105 | Active, not recruiting | Phase 1 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | November 18, 2020 | May 5, 2026 |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00040846 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | November 2001 | December 2009 |
| NCT00058227 | Completed | Phase 1 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | April 2003 | |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00795769 | Completed | Phase 2 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | August 8, 2008 | June 10, 2009 |
| NCT00799461 | Completed | Phase 3 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | August 2008 | |
| NCT00867529 | Completed | Phase 2 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | February 2009 | March 26, 2015 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00003196 | Completed | N/A | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | September 1997 | April 2002 |
| NCT00005799 | Completed | N/A | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | November 1999 | |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01233921 | Completed | N/A | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | September 2010 | |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01748721 | Completed | Phase 1 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2013 | May 2015 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01959477 | Completed | Early Phase 1 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | March 2014 | April 2015 |
| NCT02037256 | Completed | N/A | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | July 2011 | January 21, 2015 |
| NCT00089076 | Terminated | Phase 1/Phase 2 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | June 2004 | October 2009 |
| NCT00933985 | Terminated | Phase 1 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | June 2009 | April 2013 |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT01408043 | Terminated | N/A | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | October 2011 | May 2016 |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT01076270 | Terminated | N/A | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | June 2010 | February 2011 |
| NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
| NCT01678443 | Terminated | Phase 1 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | September 1, 1999 | September 27, 2018 |
| NCT02109224 | Terminated | Phase 1 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | September 2014 | July 2015 |
| NCT01769222 | Terminated | Phase 1 | Ipilimumab and Local Radiation for Selected Solid Tumors | February 2013 | June 2015 |
| NCT02168907 | Terminated | Phase 1 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | December 2014 | February 2015 |
| NCT01805037 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | March 5, 2013 | December 31, 2018 |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT02281279 | Withdrawn | Phase 1/Phase 2 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | October 2016 | |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 |
- Disase is a (Disease Ontology)
- DOID:285
- Disase is a (Disease Ontology)
- DOID:712
- Cross Reference ID (Disease Ontology)
- ICD10CM:C91.42
- Cross Reference ID (Disease Ontology)
- NCI:C142882
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279780